RecruitingPhase 2NCT06280105

A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib

Studying Pediatric hepatocellular carcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Meng Chao Hepatobiliary Hospital of Fujian Medical University
Intervention
Cadonilimab+regorafenib(drug)
Enrollment
40 enrolled
Eligibility
18-75 years · All sexes
Timeline
2024 – 2027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06280105 on ClinicalTrials.gov

Other trials for Pediatric hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Pediatric hepatocellular carcinoma →

← Back to all trials